How many insider trades does FilingIQ track for KALA?

FilingIQ tracks 290 Form 4 insider transactions for KALA (KALA BIO, Inc.), covering filings from Jul 19, 2017 onwards. 0 of those were filed in the last 90 days.

Are KALA insiders net buyers or net sellers?

Across the full Form 4 history for KALA, 34 transactions (12%) were open-market purchases and 80 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KALA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KALA in?

KALA BIO, Inc. (KALA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $346.85M.

KALA insider trading

NasdaqCM Healthcare

KALA BIO, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

290

Last 90 days

Buys / sells

12% / 28%

Market cap

$346.85M

About KALA BIO, Inc.

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Company website: www.kalarx.com

KALA insider activity at a glance

FilingIQ has scored 290 insider transactions for KALA since Jul 19, 2017. The most recent filing in our index is dated Dec 18, 2025.

Across the full history, 34 open-market purchases and 80 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KALA insider trades is 59.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KALA trades on FilingIQ Raw filings on SEC EDGAR

Latest KALA Form 4 filings

Reumuth Mary CHIEF FINANCIAL OFFICER

S Oct 22, 2025

Brazzell Romulus K SEE REMARKS

S Oct 22, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for KALA?: FilingIQ tracks 290 Form 4 insider transactions for KALA (KALA BIO, Inc.), covering filings from Jul 19, 2017 onwards. 0 of those were filed in the last 90 days.
Are KALA insiders net buyers or net sellers?: Across the full Form 4 history for KALA, 34 transactions (12%) were open-market purchases and 80 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KALA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KALA in?: KALA BIO, Inc. (KALA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $346.85M.

Methodology & sources

Every KALA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.